esg performance summary report report trust longterm priority commitment essential achieve purpose datum summary drive longterm growth add value society sasb index united nations global compact shareholder communication progress global reporting initiative commitment support report guideline trust priority drive progress document provide comprehensive assurance report key area significant summary environmental social public policy available online impact ensure running governance esg datum business responsible way business complement wider report responsible business commitment seek address annual report report progress annual report material topic relevant trust commitment stakeholder engagement stakeholder business responsible business page gskcom progress trust commitment design help respond climate change resilience tcfd challenge opportunity industry society broadly online reporting contribute materiality assessment sustainable development goal human right sciencele global healthcare sustainable development goal company big contribution political advocacy goal ensure healthy life patient group funding promote wellbee age trade association membership charitable grant contribution cautionary statement criterion work public policy group document cautionary statement forwardlooke statement modern slavery act statement march commitment commitment detailed support trust priority drive progress key area significant impact ensure run business responsible way report progress gsk annual report science make modern technology product affordable employer address health need available new medical innovation pricing engage people develop differentiate highquality need medicine improve health million people year make achieve maintain competitive employee engagement vaccine consumer healthcare product improve product available responsible price score health sustainable business inclusion diversity global health product reach accelerate progress inclusion diversity including improve global health impact infectious use access strategy reach million undeserved aspirational target female ethnically diverse disease affect child young people develop people develop country product representation senior role end recognition disability confident employer lgbt indice country focus hiv malaria healthcare access health security partner improve disease prevention awareness health wellbeing development help world well prepare future disease outbreak access healthcare service million people lead company support employee health wellbee personal development pandemic potential tackle antimicrobial resistance responsible business reliable supply ethic value datum engagement environment commit quality safety reliable supply operate ethical valuesdriven culture use datum responsibly transparently net zero impact climate net product patient consumer issue respond swiftly improve patient scientific engagement positive impact nature transparently gsk esg performance summary march data summary note general company information employee europe international total employee fte financial total operating profit pharmaceutical business revenue vaccine business revenue consumer business revenue total revenue community cash million investment total product inkind million time million management cost million total access affordability dose synflorix vaccine supply gavi million dose rotarix vaccine supply gavi million albendazole tablet donate help eliminate lymphatic filariasis million albendazole tablet donate help treat intestinal worm million value gsk medicine vaccine prescribe patient assistance programme cog million usd year change list net price change combine average net price pharmaceutical vaccine portfolio previous year change average list price previous year year list net price cagr compound growth rate change net price discount rebate allowance product past year change average list price past year new methodology fully account administrative cost bridge access benlystanucala patient assistance program lead significant increase management cost ass drug administration programme disruptedpause covid pandemic lead reduce donation number alculate gsk viiv healthcare product gsk esg performance summary march data summary continue total note access affordability continued product reach target people access generic dolutegravir product voluntary chronic ongoing treatment include cumulative total number license agreement million access annual data baseline estimate child reach synflorix gavi base dose course estimate wastage estimate child reach rotarix gavi base dose course estimate wastage estimate girl reach cervarix gavi base dose course estimate wastage estimate people reach oral polio vaccine opv base recommend dose polioendemic country estimate wastage people reach patient assistance programme people reach product access strategy health access target people access healthcare service worker educational session million work save child baseline people access malaria services comic relief partnership healthcare worker train partner people access healthcare worker service facility result health worker training programme people reach viiv healthcare positive action child fund pacf grant children access treatmentcare cleft condition smile train partnership hcpspharmacist train partner asia india dengue programme pause fever programme agreement ngo partner shift focus covid relief effort people access dengue fever service partner india programme pause agreement ngo partner shift focus covid relief effort people reach programme improve disease prevention awareness access healthcare service gavi distribute different time year provide dose potential reach state number people datum drive combination routine programme multiage cohort hpv demonstration project datum estimate base previous reach partner programme level fund final datum available april capture figure frontline health worker training programme new ceo roundtable collaboration gsk esg performance summary march data summary continue note people engagement employee survey engagement score employee survey response rate gender diversity percentage woman employee svpvp level director level manager level total woman management percentage woman board percentage female stemrelate position health safety number fatality employee complementary worker assure dnv gsk direct supervision fatality contractor gsk direct supervision reportable incident lose time assure dnv lose time reportable injury illness rate hour work assure dnv reportable incident lose time assure dnv reportable injury illness rate hour work assure dnv hour work million talent leadership number graduate recruit future leader programme development number postgraduate recruit esprit programme number apprentice recruit gsk esg performance summary march data summary continue note people continue employee turnover overall turnover calculate number permanent employee leave gsk reason divide average permanent headcount turnover voluntary leaver calculate number permanent employee voluntarily leave gsk divide average permanent headcount gender split permanent leaver calculate number permanent employee leave gsk reason period male female male female divide total number permanent leaver leave reason period overall turnover male overall turnover female hiring total number new hire open position fill internal candidate internal hire workforce breakdown year old age include year old permanent temporary employee year old gsk esg performance summary march data summary continue svpvp director manager employee people continue ethnic diversity ethnically diverse total american indian alaska native asian black african american hispanic latinx native hawaiian pacific islander race white total ethnic diversity ethnically diverse total asian black mixed white total datum represents respond identify race ethnicity category employee actively respond identify race ethnicity category indicate prefer actively respond indicate prefer year report ethnicity datum comparable historic datum start report report insufficient datum report few employee gsk esg performance summary march data summary continue note environment energy natural gas gwh coal gwh electricity gwh electricity purchase gwh steam hot water gwh fuel gwh energy biomass gwh onsite generate renewable electricity gwh purchase renewable electricity gwh assure dnv renewable electricityused electricity total energy gwh assure dnv carbon scope onsite fuel use thousands tonne emission sale force vehicle thousands tonne propellant emission manufacture inhaler thousands tonne onsite waste waste water treatment thousand tonne refrigerant gas loss thousands tonne total scope emission thousand tonne assure dnv electricity marketbase emission thousand tonne steamhot water thousand tonne compress air thousand tonne chill water thousand tonne total scope emission marketbase thousands tonne assured dnv scope locationbase emission thousand tonne assure dnv total scope emission marketbase thousands tonne assure dnv fermentationbiogenic release thousands tonne gsk esg performance summary march data summary continue note environment continue carbon scope purchase good service thousands tonne emission capital good thousand tonne fuel energy relate activity thousands tonne transportation distribution upstream thousand tonne waste generate operation thousands tonne business travel thousands tonne employee commute thousand tonne lease asset upstream thousand tonne transportation distribution downstream thousands tonne processing sell product thousand tonne use sell product thousand tonne mission use propellant base inhaler patient assure dnv thousand tonne end life thousand tonne lease asset downstream thousands tonne franchise thousand tonne investment thousand tonne total scope emission thousand tonne ozone deplete odp investory cfc hcfc equipment cfce substance odp calculate release cfc equiv cfce water use municipal million ground water million tanker million total water use million assure dnv recycle source million water use high water risk site million assure dnv propellant emission datum collect internal system accurate picture scope ghg emission late year mission classify downstream transportation previous year reclassify upstream transportation emission advice carbon trust gsk high water risk site gsk esg performance summary march data summary continue note environment continue water discharge wastewater municipal sewer million wastewater surface water million wastewater million wastewater discharge land million wastewater recharge aquifer rainwater million wastewater recharge aquifer treat effluent million total wastewater discharge million assure dnv waste beneficial use hazardous waste thousand tonne beneficial use nonhazardous waste thousand tonne total beneficial use waste thousand tonne assure dnv nonbeneficial use hazardous waste thousand tonne nonbeneficial use nonhazardous waste thousand tonne total nonbeneficial use waste thousand tonne assure dnv total overall waste thousand tonne assure dnv hazardous waste landfill thousand tonne nonhazardous waste landfill thousand tonne total waste landfill thousand tonne assure dnv percentage waste send beneficial use compliance ehs internal audits gsk site facility ehs ethic labour right audits party supplier environmental fine environmental spend million remediation responsibility remove pollution contaminant soil surface ground water facility previously disposal site waste management company gsk esg performance summary march data summary continue note ethical conduct compliance percentage employee agree work environment encourage ethical behaviour face pressure meet business objective employee discipline policy violation breakdown type policy violation behaviour workplace mandatory training completion good manufacturing distribution practice market promotional activity expense employee dismiss agree leave company voluntarily document warning political engagement spend federal lobbying activity datum register federal lobbying register include cost operating office washington cost travel consulting cost represent interest institution datum publish transparency register political action committee contribution employee state federal breakdown pac spend available online candidate clinical trial transparency clinical trial datum publicly available trial result summarie cumulative study clinical study report post register trial list patient level datum available request research team approve access gsk trial datum change way collect disciplinary datum improve clarity example remove number category deem behavioural policy violation sanction result absence work illness reduce number reflect change individual employee subject multiple allegation result disciplinary action policy violation type fit category specify include late available figure previous year figure report year publish april publication document new methodology introduce gsk esg performance summary march data summary continue note product safety quality quality safety audits party quality process audits clinical trial audits trial conduct party behalf ensure quality regulatory inspection pharmaceutical business manufacture regulatory inspection vaccine business supply regulatory inspection consumer healthcare business total product recall number fda product pharmaceutical recall business vaccine class iiiiii consumer healthcare number fda pharmaceutical enforcement action vaccine take response consumer healthcare violation current good manufacturing practice cgmp lass iii recall represent total consumer healthcare product produce globally comprise class recall class iii represent total consumer healthcare product batch manufacture gsk esg performance summary march environmental data terminology kpi definition method report boundary publish environmental datum cover facility own lease gsk gsk publish datum align calendar year joint venture partner gsk operational control december value include estimate base december small commercial office distribution centre require report value actual datum available time publication datum environmental impact follow criterion meet restate correct december estimate report period total energy usage mwh annum baseline year environmental target total water annum environmental data site join gsk network total waste generate tonne annum gskpfizer consumer healthcare integrate gsk datum ensure gsk report environmental impact energy includes purchase energy grid electricity natural gas coal energy datum base invoice datum utility company diesel fuel renewably generate energy solar wind meter reading biomass purchase renewable electricity allocate site evidence purchase renewable electricity renewable electricity generate supplier supply contract place retirement certificate origin purchase supply agreement include evidence origin occur report period rec rego power purchase agreement ppa water include water supply withdraw gsk water datum base invoice datum supplier meter reading site capture rainwater recycle water measure report include total water calculation high water risk include water supply site identify gsk high water risk gsk map geographic location site output site assessment tool wri aqueduct wwfdeg water risk filter identify site region highwater stress gsk originally identify high risk water site network change currently seven high risk water site network detailed water stewardship risk assessment cover local water availability water quality local regulatory framework cape town south africa access water sanitation perform classify boudouaou algeria site determined gsk high water risk site jamshoro pakistan karachi pakistan follow review site xochimilco mexico karachi west wharf pakistan remove site jamshoro pakistan add list nashik india high water risk site datum restate reflect oak hill usa change gsk complete water stewardship risk assessment site join network pfizer consumer healthcare waste water include wastewater send municipal sewer discharge surface wastewater datum base invoice datum utility company water treatment site waste water irrigation wastewater meter reading calculation base water use absence recharge aquifer accordance local regulation meter liquid waste waste solvent contain water report separately waste gsk esg performance summary march environmental data terminology continue kpi definition method scope carbon emission gsk scope emission cover emission direct combustion fuel carbon emission calculate equivalent ghg site generate heat electricity emission sale force protocol corporate accounting reporting standard vehicle fugitive loss propellant manufacturing inhaler carbon emission factor calorific factor combustion loss refrigerant gsk own ancillary equipment natural gas diesel coal fuel take onsite waste waste water treatment government emission conversion factor greenhouse gas company report edition carbon emission sale force travel calculate base distance travel directly fuel use add estimate approx office distance drive datum available carbon emission refrigerant loss base quantity refrigerant equipment biogenic emission report separately include scope total emission scope carbon emission gsk scope emission include purchase electricity steam compress carbon emission factor purchase electricity take air chill water international energy agency statistic fuel combustion edition gsk use marketbase scope emission reporting purpose carbon emission factor purchase heat steam chill water take government emission conversion factor greenhouse gas company report edition gsk restate scope emission electricity base update iea emission factor publish gsk report marketbase scope emission facility evidence utility provider low carbon energy generation certificate origin rec rego ppa hydroelectric local grid supply quebec region scope carbon emission gsk report scope category detail greenhouse gas scope datum category prepare gsk protocol hybrid model combine primary activitybased datum available economic data model quality assure carbon trust scope emission business travel air base ticket information directly fuel use scope emission patient use meter dose inhaler base number inhaler leave manufacturing site distribution propellant inhaler gsk esg performance summary march environmental data terminology continue kpi definition method waste waste generate operational waste leave gsk boundary waste datum base invoice waste transfer note datum beneficial use waste define waste send recycling reuse incineration energy recovery nonbeneficial use waste define waste dispose incineration energy recovery send landfill waste landfill waste landfill include hazardous nonhazardous waste waste landfill data base invoice waste transfer note dispose landfill datum case local law regulation require certain waste send landfill type waste asbestos waste landfill good environmental option include waste waste send landfill datum table allow small number site affect claim zero landfill status ozone deplete substance report ozone deplete potential total ozone deplete total ozone deplete substance base site contain equipment substance contain ancillary equipment cfc equivalent inventory datum multiply ozone deplete potential factor intergovernmental panel climate change estimate impact fugitive loss refrigerant exclude inventory small number site gsk manage refrigeration equipment gsk reportable incident gsk reportable injury illness meet follow criterion consistent global reporting gsk reportable injury illness meet list criterion criterion different affect individual gsk employee complementary worker national regulatory reporting requirement vary direct gsk daily supervision world incident work relate lose time incident result day away outcome involve follow work job restriction employee unable perform fatality routine activity lose restrict day count day follow incident loss consciousness hour work calculate base number work day medical treatment aid year length average workday number employee significant occupational injury occupational illness diagnose site provide gsk human resource employee include physician license health care professional time employee directly supervise agency staff restrict dayschange job dutiesday away work gsk restate incident datum account small new case number incident occur record complete table prepare year incident rate calculate hour work gsk esg performance summary march list product list prequalifie medicinal product vaccine prequalification medicine programme pqp type form presentation date prequalification vaccine engerix hepatitis liquid ready use vial dose thursday january engerix hepatitis liquid ready use vial dose thursday january engerix hepatitis liquid ready use vial dose thursday january priorix measle mump rubella lyophilise active component reconstitute excipient friday march diluent use vial dose rotarix rotavirus liquid ready use plastic tube dose thursday march rotarix rotavirus liquid ready use applicator dose thursday march cervarix human papillomavirus bivalent liquid ready use vial dose wednesday july cervarix human papillomavirus bivalent liquid ready use vial dose wednesday july polio sabin mono polio vaccine oral opv monovalent type liquid ready use vial dose thursday october polio sabin mono polio vaccine oral opv monovalent type liquid ready use vial dose thursday october polio sabin polio vaccine oral opv bivalent type liquid ready use vial dose thursday october polio sabin polio vaccine oral opv bivalent type liquid ready use vial dose thursday october synflorix pneumococcal conjugate liquid ready use vial dose friday october synflorix pneumococcal conjugate liquid ready use vial dose friday march poliorix polio vaccine inactivate ipv liquid ready use vial dose thursday august poliorix polio vaccine inactivate ipv liquid ready use vial dose thursday august polio sabin mono oral polio vaccine oral opv monovalent type liquid ready use vial dose tuesday october polio sabin mono oral polio vaccine oral opv monovalent type liquid ready use vial dose tuesday october polio sabin mono oral polio vaccine oral opv monovalent type liquid ready use vial dose wednesday polio sabin mono oral polio vaccine oral opv monovalent type liquid ready use vial dose wednesday priorix measle mump rubella lyophilise active component reconstitute excipient wednesday december diluent use vial dose havrix adult hepatitis human diploid cell inactivate adult liquid ready use vial dose friday july havrix junior hepatitis human diploid cell inactivate paediatric liquid ready use vial dose friday july boostrix diphtheriatetanuspertussis acellular liquid ready use vial dose tuesday july menveo meningococcal acyw conjugate vaccine lyophilise active component reconstitute wednesday july liquid active component use vial set dose synflorix pneumococcal conjugate liquid ready use vial dose monday october rotarix rotavirus liquid ready use plastic tube dose thursday february gsk esg performance summary march list product list prequalifie medicinal product vaccine prequalification medicine programme pqp continue type applicant ref number date prequalification pharmaceutical abacavir sulfate hiv viiv healthcare march abacavir sulfate hiv viiv healthcare march zidovudine hiv viiv healthcare zidovudine hiv viiv healthcare lamivudinezidovudine hiv viiv healthcare march zidovudine hiv viiv healthcare march zidovudine hiv viiv healthcare march lamivudine hiv viiv healthcare march lamivudine hiv viiv healthcare march dolutegravir sodium hiv viiv healthcare october abacavir sulfatelamivudine hiv viiv healthcare june zanamivir influenza gsk september gsk esg performance summary march sasb index produce sustainability accounting standard board sasb index illustrate reporting align biotechnology pharmaceutical industry guideline continue align reporting sasb future report data information report range source include public policy annual report esg performance summary gskcom index signpost relevant source gsk esg performance summary march sasb index sasb indicator find information safety clinical trial participant hcbpa discussion world region management process ensure quality patient safety clinical trial clinical trial policy hcbpa number fda sponsor inspection relate clinical trial management pharmacovigilance resulted report voluntary action indicate vai official action indicate oai hcbpa total monetary loss result legal proceeding associate clinical trial develop report country access medicine hcbpa description action initiative promote access health care product priority disease annual report priority country define access medicine index hcbpa list product list prequalifie medicinal product prequalification medicine document programme pqp affordabilty pricing hcbpb number settlement abbreviate new drug application anda litigation involve payment andor report provision delay bring authorized generic product market define time period hcbpb percentage change average list price average net price product portfolio compare document previous year hcbpb percentage change list price net price product large increase compare document previous year drug safety hcbpa list product list food drug administration fda medwatch safety alert available human medical product database fda adverse event report website hcbpa number fatality associate product report fda adverse event report system available fda adverse event report website hcbpa number fda recall issue total unit recall document hcbpa total product accept takeback reuse disposal report hcbpa number fda enforcement action take response violation current good manufacturing practice document cgmp type gsk esg performance summary march sustainability disclosure topic accounting metric continue counterfeit drug hcbpa description method technology maintain traceability product annual report supply chain prevent counterfeiting falsify substandard healthcare product hcbpa discussion process alert customer business partner potential know risk annual report associate counterfeit product hcbpa number action lead raid seizure arrest andor filing criminal charge relate report counterfeit product ethical marketing hcbpa total monetary loss result legal proceeding associate false marketing claim report hcbpa description code ethic govern promotion offlabel use product arkete practice scientific engagement employee recruitment development retention hcbpa discussion talent recruitment retention effort scientist research development personnel annual report hcbpa voluntary involuntary turnover rate executivessenior manager midlevel report turnover gender manager professional report supply chain management hcbpa percentage entitys facility tier supplier facility participate gsk member international pharmaceutical supply chain consortium audit program equivalent thirdparty audit conduct audits party program integrity supply chain ingredient business ethic hcbpa total monetary loss result legal proceeding associate corruption bribery report hcbpa description code ethic govern interaction health care professional ode practice promotion prescription medicine scientific engagement activity metric hcbpa number patient treat annual report patient reach access strategy hcbpb number drug portfolio research development phase annual report pipeline online product gsk esg performance summary march united nations statement support ceo gsk remain committed uphold global compact ungcs principle human right environment anticorruption aim embed policy standard business gsk signatory global compact ungc remain true value compact challenge business operate accord purpose help people principle cover bribery corruption feel well live long human right labour environment follow emma walmsley index structure accord criterion chief executive officer march advanced level communication progress cop compile annual report gskcom website gsk esg performance summary march united nations global compact communication progress annual report find datum online implement principle strategy mainstreame place responsibility execution sustainability strategy relevant corporate function governance structure corporate function procurement government affair human resource legal etc ensure function conflict business unit company sustainability commitment objective align strategy goal incentive structure business unit subsidiarie longterm priority corporate sustainability strategy apply business assign responsibility corporate sustainability implementation individual governance structure group business unit subsidiary describe value communicate policy expectation supplier relevant business partner work party chain implementation implement monitoring assurance mechanism audits screening compliance work party company sphere influence undertake awarenessraising training type capacity build supplier work party business partner carbon robust human right management policy procedure robust commitment commitment comply applicable law respect internationally recognise human right gsk human right statement strategy policy company operate area human right integrate standalone statement policy express commitment respect support gsk human right statement human right approve senior level company statement policy publicly available communicate internally externally personnel gsk human right statement business partner relevant party describe effective ongoing diligence process include assessment actual potential human right human right management system impact integrate human allocation responsibility accountability address human right impact human right right principle describe effective relevant policy procedure activity company plan undertake fulfil human right monitoring evaluation criterion include goal timeline metric responsible staff gsk human right statement mechanism human right integration system monitor effectiveness human right policy implementation quantitative human right qualitative metric include supply chain gsk human right statement gsk esg performance summary march united nations global compact communication progress continue robust labour management policy procedure continue describe robust reference principle relevant international labour standard gsk human right statement commitment ilo convention normative international instrument company policy strategy policie inclusion reference principle contain relevant international labour standard human right area labour contract supplier relevant business partner describe effective risk impact assessment area labour work party management system grievance mechanism communication channel procedure whistleblow ethic value integrate labour mechanism available worker report concern suggestion seek advice practice design operate agreement representative organisation worker describe effective audits step monitor improve working condition company supply chain work party monitoring evaluation line principle international labour standard mechanism labour process positively engage supplier address challenge scheme improve work party principle integration workplace practice robust environmental management policy procedure describe robust reflection relevance environmental stewardship company environment commitment strategy write company policy environmental stewardship climate change policy area gsk operation environmental stewardship inclusion minimum environmental standard contract supplier relevant work party business partner carbon specific commitment goal specify year environment describe effective environmental risk impact assessment climaterelate financial management system disclosure integrate water stewardship policy environmental principle allocation responsibility accountability organisation governance structure describe effective system track measure performance base standardised performance metric environment monitoring evaluation mechanism audits step monitor improve environmental performance company work party environmental supply chain stewardship gsk esg performance summary march united nations global compact communication progress continue robust anticorruption management policy procedure describe robust publicly state formal policy zerotolerance corruption antibribery corruption commitment strategy policy policy area policy anticorruption business partner antibribery corruption anticorruption policy party guideline describe effective support organisation leadership anticorruption ethic value management system internal check balance ensure consistency anticorruption commitment ethic value integrate anti corruption principle management responsibility accountability implementation anticorruption commitment ethic value policy communication whistle blow channel followup mechanism report concern ethic value seek advice speakup integrity line describe effective leadership review monitor improvement result ethic value monitoring evaluation mechanism integration anti corruption take action support global goal describe core business align core business strategy relevant goalsissue sdg factsheet contribution goal issue develop relevant product service design business model contribute goalsissues science technology affordability availability describe strategic pursue social investment philanthropic contribution tie core competency science technology social investment operate context company integrate sustainability strategy affordability availability philanthropy describe advocacy publicly advocate importance action relation goalsissue sdg factsheet public policy commit company leader participate key summit conference important public policy sdg factsheet engagement interaction relation goalsissues gsk esg performance summary march united nations global compact communication progress continue take action support global goal continue describe partnership develop implement partnership project public private organisation core business product reach healthcare collective action social investment andor advocacy access join industry peer entities andor stakeholder initiative contribute solve common product reach healthcare challenge dilemmas global andor local level emphasis initiative extend access company positive impact value chain corporate sustainability governance leadership describe ceo ceo publicly deliver explicit statement demonstrate personal leadership sustainability ungc cop ceo statement commitment commitment global compact leadership ceo promote initiative enhance sustainability company sector lead development ceo statement industry standard describe board adoption board director equivalent assume responsibility oversight longterm corporate committee report oversight sustainability strategy performance ceo statement board establishe permissible committee assigns individual board member committee report responsibility corporate sustainability board committee permissible approve formal report corporate sustainability committee report communication progress governance describe stakeholder publicly recognise responsibility company impact internal external stakeholder stakeholder engagement engagement define sustainability strategy goal policy consultation key stakeholder stakeholder engagement establish channel engage employee stakeholder hear idea address ethic value concern protect whistle blower speak integrity gsk esg performance summary march global reporting initiative guideline base report gri guideline produce gri index element gri standard cover reporting help comparison company report gsk esg performance summary march global reporting initiative guideline gri standard number description number responselink response general disclosure organization glaxosmithkline plc activity brand product service httpwwwannualreportgskcom location headquarters brentford middlesex location operation country ownership legal form httpwwwannualreportgskcom market serve httpwwwannualreportgskcom scale organisation httpwwwannualreportgskcom information employee worker httpwwwannualreportgskcom supply chain httpwwwannualreportgskcom significant change organisation supply chain httpwwwannualreportgskcom precautionary principle approach httpwwwannualreportgskcom externally develop economic environmental social httpwwwannualreportgskcom charter principle initiative organization subscribe endorse membership association httpswwwgskcomengbresponsibilityresponsibilityreportsdata patientgroupfunde httpswwwgskcomengbresponsibilityresponsibilityreportsdata tradeassociationmembership statement senior decisionmaker httpwwwannualreportgskcom value principlesstandard norm behaviour httpwwwannualreportgskcom governance structure organization include committee httpswwwgskcomengbresponsibility high governance body responsible decisionmake economic environmental social topic list stakeholder group httpwwwannualreportgskcom identify select stakeholder httpsgskcommediamaterialityassessmentpdf approach stakeholder engagement httpwwwannualreportgskcom key topic concern raise httpsgskcommediamaterialityassessmentpdf gsk esg performance summary march global reporting initiative guideline continue gri standard number description number responselink response change report significant change report period jandec date recent report report cycle annual contact point question report csrcontactgsk com claim report accordance gri standard httpswwwgskcomengbresponsibilityresponsibilityreportsdata reportingarchiveandresources gri content index external assurance document specific standard disclosure economic economic performance httpsgskcommediamaterialityassessmentpdf generic disclosure management approach direct economic value generate distribute httpwwwannualreportgskcom indirect economic impact httpsgskcommediamaterialityassessmentpdf generic disclosure management approach significant indirect economic impact include extent httpwwwannualreportgskcom impact anticorruption httpsgskcommediamaterialityassessmentpdf generic disclosure management approach communication training anticorruption httpwwwannualreportgskcom approach tax httpswwwgskcommediataxstrategypdf tax governance control risk management httpswwwgskcommediataxstrategypdf gsk esg performance summary march global reporting initiative guideline continue gri standard number description number responselink response social occupational health safety httpwwwannualreportgskcom generic disclosure management approach rate injury occupational disease lose day absenteeism document work relate fatality train education httpwwwannualreportgskcom generic disclosure management approach employee receive regular performance career httpwwwannualreportgskcom development review diversity httpwwwannualreportgskcom generic disclosure management approach diversity governance body employee httpwwwannualreportgskcom society marketing labelling httpsgskcommediamaterialityassessmentpdf generic disclosure management approach incident noncompliance concern product service httpswwwgskcomengbresponsibilityoperatingresponsibly information label human right httpwwwannualreportgskcom generic disclosure management approach environment energy consumption organization document reduction energy consumption httpwwwannualreportgskcom document reduction energy requirement product service httpwwwannualreportgskcom water httpsgskcommediamaterialityassessmentpdf generic disclosure management approach water withdrawal document water discharge document gsk esg performance summary march gri standard number description number responselink response climate change httpwwwannualreportgskcom generic disclosure management approach direct scope ghg emission document energy indirect scope ghg emission document indirect scope ghg emission httpwwwannualreportgskcom document ghg emission intensity httpwwwannualreportgskcom emission ozonedeplete substance od document waste packaging httpsgskcommediamaterialityassessmentpdf generic disclosure management approach water discharge quality destination document waste type disposal method document noncompliance environmental law regulation document inclusion standard necessitate gsk publish breakdown scope ghg emission esg performance summary gsk esg performance summary march gsk esg performance summary march gsk esg performance summary march public policy available online public policy position gskcom provide information number number issue include topic include antimicrobial resistance materiality assessment care welfare treatment animal human right clinical trial develop world sustainable development goal clone stem cell technology political advocacy code conduct patient group funding deforestation free source trade association membership impact climate change health charitable grant contribution genetically modify microorganism environment criterion work public policy group health safety eh modern slavery act statement marketing practice scientific engagement prepare future disease threat nanotechnology ozone depletion metereddose inhaler asthma pharmaceuticals environment pie pharmacovigilance tax strategy work party gsk esg performance summary march cautionary statement document contain forwardlooke statement forward authority group undertake obligation update forward look statement group current expectation forecast look statement result new information future future event investor identify statement fact event investor consult additional relate strictly historical current fact use disclosure group document word anticipate estimate expect intend project publish andor file security exchange plan believe target word term similar meaning commission sec investor locate note connection discussion future operate financial disclosure accordingly assurance give performance particular include statement relate particular expectation meet investor caution future action prospective product product approval future place undue reliance forwardlooke statement forward performance result current anticipate product sale look statement subject assumption inherent risk effort expense outcome contingency legal uncertainty relate factor proceeding dividend payment financial result group control precise estimate group caution investor accordance legal regulatory obligation include number important factor include market abuse regulation list rule disclosure presentation cause actual result differ materially guidance transparency rule financial conduct express imply forwardlooke statement gsk esg performance summary march